Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Гипогликемии как основной фактор выбора целей гликемического контроля и тактики лечения больных сахарным диабетом типа 2
Гипогликемии как основной фактор выбора целей гликемического контроля и тактики лечения больных сахарным диабетом типа 2
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Morrish NJ, Wang SL, Stevens LK et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44 (Suppl. 2): 14–21.
2. Gore MO, McGuire DK. The 10-year posttrial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): cardiovascular observations in context. Diab Vasc Dis Res 2009; 6: 53–5.
3. Desouza C, Bolli G, Fonseca V. Hypoglycemia, Diabetes, and Cardiovascular Events. Diabetes Care 2010; 33: 1389–94.
4. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med 2008; 25: 245–54.
5. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 5-е изд. Под ред. И.И.Дедова, М.В.Шестаковой. М., 2011.
6. Murad MH, Coto-Yglesias F, Wang AT et al. Clinical review: Drug-induced hypoglycemia: a systematic review. J Clin Endocrinol Metab 2009; 94: 741.
7. Аметов А.С., Иванова Е.В. Гипогликемия. Сахарный диабет 2 типа. Проблемы и решения. М.: ГЭОТАР- Медиа, 2011: 115–43.
8. Miller DR, Finckel G, Lafrance JP et al. Hypoglycaemia and risk of myocardial infarction in U.S. veterans with Diabetes. EASD 2009. Diabetologia 2009; 52 (Suppl. 1): 63.
9. Alvarez GF, Tofe PS, Krishnarajah G et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAPDM) Study. Diabetes Obes Metab 2008; 10 (Suppl. 1): 25–32.
10. Zoungas S, Patel A, Chalmers J et al. Severe Hypoglycemia and Risks of Vascular Events and Death. N Engl J Med 363; 15 okt 7, 2010.
11. Zoungas S, Turnbull F. Intensive glucose-lowering therapy in people with type 2 diabetes: what do we learn from a new meta-analysis of randomised controlled trials? Evid Based Med 2012; 17 (3): 98–9. Epub 2011 Nov 28.
12. Dejager S, Schweizer A. Minimizing the risk of hypoglycemia with Vildagliptin: clinical experience, mechanistic basis, and importance in type 2 diabetes management. Diab ther 2011; 2 (2): 51–66.
13. Анциферов М.Б., Дорофеева Л.Г. Вилдаглиптин – новый препарат из класса ингибиторов дипептидилпептидазы-4 для лечения сахарного диабета типа 2. Новые лекарственные средства и технологии. Фарматека, 2009; 3.
14. Rosenstock J, Foley JE, Rendell M et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008; 31: 30–5.
15. Scherbaum WA, Schweizer A, Mari A et al. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008; 10: 675–82.
16. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76: 132–8.
17. Schweizer A, Dejager S, Foley JE. Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy ofvildagliptin. Diabetes Ther 2012; 3 (1): 8. Epub 2012 Jun 27.
18. Дедов И.И., Шестакова М.В. Инкретины: новая веха в лечении сахарного диабета 2 типа. Практическое руководство для врачей. М., 2010.
19. Kothny W, Shao Q, Groop P-H, Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab 2012; 14 (11): 1032–9.
20. Blüher M, Kurz I, Dannenmaier S, Dworak M. Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study. World J Diabetes 2012; Vol. 15; 3 (9): 161–9.
21. Devendra D, Gohel B, Bravis V et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract 2009; 63: 1446–50.
22. Garber AJ, Schweizer A, Baron MA et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007; 9: 166–74.
23. Garber AJ, Foley JE, Banerji MA et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008; 10: 1047–56.
24 .Kikuchi M, Haneda M, Koya D et al. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2010; 89: 216–23.
25. Fonseca V, Schweizer A, Albrecht D et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50: 1148–55.
2. Gore MO, McGuire DK. The 10-year posttrial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): cardiovascular observations in context. Diab Vasc Dis Res 2009; 6: 53–5.
3. Desouza C, Bolli G, Fonseca V. Hypoglycemia, Diabetes, and Cardiovascular Events. Diabetes Care 2010; 33: 1389–94.
4. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med 2008; 25: 245–54.
5. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 5-е изд. Под ред. И.И.Дедова, М.В.Шестаковой. М., 2011.
6. Murad MH, Coto-Yglesias F, Wang AT et al. Clinical review: Drug-induced hypoglycemia: a systematic review. J Clin Endocrinol Metab 2009; 94: 741.
7. Аметов А.С., Иванова Е.В. Гипогликемия. Сахарный диабет 2 типа. Проблемы и решения. М.: ГЭОТАР- Медиа, 2011: 115–43.
8. Miller DR, Finckel G, Lafrance JP et al. Hypoglycaemia and risk of myocardial infarction in U.S. veterans with Diabetes. EASD 2009. Diabetologia 2009; 52 (Suppl. 1): 63.
9. Alvarez GF, Tofe PS, Krishnarajah G et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAPDM) Study. Diabetes Obes Metab 2008; 10 (Suppl. 1): 25–32.
10. Zoungas S, Patel A, Chalmers J et al. Severe Hypoglycemia and Risks of Vascular Events and Death. N Engl J Med 363; 15 okt 7, 2010.
11. Zoungas S, Turnbull F. Intensive glucose-lowering therapy in people with type 2 diabetes: what do we learn from a new meta-analysis of randomised controlled trials? Evid Based Med 2012; 17 (3): 98–9. Epub 2011 Nov 28.
12. Dejager S, Schweizer A. Minimizing the risk of hypoglycemia with Vildagliptin: clinical experience, mechanistic basis, and importance in type 2 diabetes management. Diab ther 2011; 2 (2): 51–66.
13. Анциферов М.Б., Дорофеева Л.Г. Вилдаглиптин – новый препарат из класса ингибиторов дипептидилпептидазы-4 для лечения сахарного диабета типа 2. Новые лекарственные средства и технологии. Фарматека, 2009; 3.
14. Rosenstock J, Foley JE, Rendell M et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008; 31: 30–5.
15. Scherbaum WA, Schweizer A, Mari A et al. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008; 10: 675–82.
16. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76: 132–8.
17. Schweizer A, Dejager S, Foley JE. Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy ofvildagliptin. Diabetes Ther 2012; 3 (1): 8. Epub 2012 Jun 27.
18. Дедов И.И., Шестакова М.В. Инкретины: новая веха в лечении сахарного диабета 2 типа. Практическое руководство для врачей. М., 2010.
19. Kothny W, Shao Q, Groop P-H, Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab 2012; 14 (11): 1032–9.
20. Blüher M, Kurz I, Dannenmaier S, Dworak M. Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study. World J Diabetes 2012; Vol. 15; 3 (9): 161–9.
21. Devendra D, Gohel B, Bravis V et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract 2009; 63: 1446–50.
22. Garber AJ, Schweizer A, Baron MA et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007; 9: 166–74.
23. Garber AJ, Foley JE, Banerji MA et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008; 10: 1047–56.
24 .Kikuchi M, Haneda M, Koya D et al. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2010; 89: 216–23.
25. Fonseca V, Schweizer A, Albrecht D et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50: 1148–55.
Авторы
Ю.Ш.Халимов, В.В.Салухов, Е.О.Улупова
Кафедра военно-полевой терапии ФГКВОУ ВПО Военно-медицинская академия им.С.М.Кирова, Санкт-Петербург
Кафедра военно-полевой терапии ФГКВОУ ВПО Военно-медицинская академия им.С.М.Кирова, Санкт-Петербург
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.